Newswise — NOVEMBER 13, 2017, NEW YORK – Ludwig Cancer Research has released the scope of its participation at this year’s Annual Meeting and Education Day of the Society for Neuro-Oncology in San Francisco, California, November 16-19. Research by Ludwig scientists will be presented in sunrise, plenary and concurrent sessions.
Ludwig scientists will share new insights on cancer cell metabolism and resistance to cancer therapy, the tumor microenvironment, potential therapeutic targets and the molecular signaling that drives brain tumor progression. Researchers will also present findings on the use of immunotherapy to treat brain cancer, including results of a Phase 2 clinical trial to evaluate a checkpoint blockade immunotherapy as a treatment for bevacizumab-refractory recurrent glioblastoma.
The meeting will be co-chaired by Frank Furnari, a member of Ludwig Institute for Cancer Research, San Diego, whose research focuses on the pathways that drive initiation and progression of glioblastomas. Exploration of glioblastoma biology and the development of new treatments for glioblastomas have long been core elements of Ludwig’s research program. Ludwig’s Director of Strategic Alliances in Central Nervous System Cancers Webster Cavenee, who has contributed enormously to this work, will receive the Lifetime Achievement Award at the meeting.
Click here for a comprehensive list of Ludwig scientists’ activities at the meeting.
# # #
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit www.ludwigcancerresearch.org.
For further information please contact Rachel Steinhardt, [email protected] or +1-212-450-1582.
MEDIA CONTACTRegister for reporter access to contact details
The 2017 Society for Neuro-Oncology Annual Meeting, Nov-2017